COVID-19: Bill & Melinda Gates Foundation

Boehringer Ingelheim, along with global life science companies, joins the Bill & Melinda Gates Foundation's COVID-19 Therapeutics Accelerator to fight the pandemic. The collaboration is designed to accelerate the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19. Boehringer Ingelheim will contribute its database of active ingredients for testing by the "Accelerator". The "Accelerator" will follow a three-pronged approach: testing approved drugs for their effectiveness against COVID-19, screening active ingredients with confirmed safety data and investigating new active ingredients and monoclonal antibodies.